A phase I study to assess the safety and tolerability of intravesical pembrolizumab in recurrent non-muscle invasive bladder cancer (NMIBC). (2019)
Attributed to:
Tumour Immunology
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1200/jco.2019.37.7_suppl.406
Publication URI: http://dx.doi.org/10.1200/jco.2019.37.7_suppl.406
Type: Journal Article/Review
Parent Publication: Journal of Clinical Oncology
Issue: 7_suppl